|

New Hope for Mesothelioma: Understanding Immunotherapy

ByHolly Zink
New Hope for Mesothelioma: Understanding Immunotherapy

Facing health challenges can be tough, especially when dealing with pleural mesothelioma. A new study shows progress in mesothelioma treatment. The breakthrough comes with a treatment called immunotherapy.

Pleural mesothelioma is a rare and tough disease. In the past, doctors used drugs to treat it, but the average survival time is only about 12 months. Now, there’s a new way of treating it that gives us a renewed sense of hope.

The Power of Immunotherapy

Our bodies have a natural defense system called the immune system. It helps fight off bad cells, like cancer. But sometimes, certain cancers, such as pleural mesothelioma, can trick the immune system. This is where immunotherapy comes in.

Scientists have developed special medicines called immune checkpoint inhibitors, like pembrolizumab and nivolumab. These medicines help the immune system fight back against cancer cells more effectively. Recent studies have shown that these medicines are promising and can make a big difference in treating mesothelioma.

Researchers are also looking at other ways to help the immune system fight mesothelioma. They are studying adoptive cell transfer therapies, therapeutic vaccines, and cytokine-based treatments. These treatments either make the body’s defenses stronger or target and destroy cancer cells. Scientists are also testing if combining different treatments, like chemotherapy, can make them even more effective.

A Glimpse of Hope

Immunotherapy is changing how we approach mesothelioma. By using the body’s own defense system, these treatments offer hope for better results and more time for those fighting this tough disease. Ongoing research and new discoveries are giving us a chance to transform how we treat pleural mesothelioma.

As we move ahead, these new treatments offer alternatives that are not only better but also less invasive. The journey might still be challenging, but with progress in immunotherapy, there’s a hopeful future for those dealing with pleural mesothelioma.

Source:

CALABRO, LUANA, Giuseppe Bronte, Federica Grosso, Luigi CERBONE, Angelo Delmonte, Fabio Nicolini, Massimiliano Mazza, Anna Maria Di Giacomo, Alessia Covre, and Maria Fortunata Lofiego. “Immunotherapy of Mesothelioma: The Evolving Change of a Long-Standing Therapeutic Dream.” Frontiers in Immunology 14 (2023): 1333661. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1333661/abstract

Similar Posts

  • | |

    Mesothelioma Study Finds New Treatment Target

    ByAlex Strauss

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | | |

    Human Trials Planned for Promising New Mesothelioma Drug

    ByAlex Strauss

    The Australian Asbestos Diseases Research Institute says it is ready to begin human trials on what its lead researcher calls the first significant advance in mesothelioma treatment in a decade. More than three years in development, TargomiRs utilizes a unique ‘minicell’ delivery system to insert a synthetic form of missing genetic material into mesothelioma cells. Like a number of other types of cancer, mesothelioma cells are missing a family of microRNAs critical to regulating the cellular life cycle. TargomiRs restores these microRNAs. In mice with human-derived mesothelioma, TargomiRs produced a “remarkable inhibition of tumour growth”, according to the Asbestos Diseases Research Institute. “The last significant development in the treatment of mesothelioma occurred ten years ago,” ADRI director Nico van Zandwijk…

  • | |

    Macrophages May Hold Key to Fighting Mesothelioma

    ByAlex Strauss

    Researchers in Western Australia are investigating new ways of bolstering the immune system in an effort to fight cancers like mesothelioma. Like most types of cancer, malignant mesothelioma occurs primarily in people over 65. That is also the time in life when the immune system typically weakens. Researchers from Curtin University and the University of Western Australia say it is no coincidence that people become more susceptible to mesothelioma as their immunity wanes. In addition to age-related immune dysfunction, mesothelioma patients experience a further decline in immunity caused by the growing tumor itself. To better understand the connection between declining immunity and the onset of mesothelioma, the researchers are focusing on a particular type of immune system cell called a macrophage….

  • | |

    Mesothelioma Study Could Improve Immunotherapy

    ByAlex Strauss

    Scientists have made an important discovery about a component of the immune system that could have an impact on mesothelioma, one of the rarest and most aggressive cancers. Although mesothelioma is rare, it claims about 2,500 lives in the U.S. annually. Scientists around the globe are searching for a method to keep this cancer from spreading across the membranes that surround the lungs or line the abdomen. As mesothelioma tumors on these membranes grow larger, the likelihood that the cancer will spread to the lungs or other internal organs increases. The immune system is designed to help stop the spread of invaders or out-of-control cancer cells. One immune cell, the Natural Killer or NK cell, is known to exert an anti-tumor effect…

  • | |

    Mesothelioma Vaccine Enters Phase 2 Testing

    ByAlex Strauss

    The makers of a new cancer vaccine say they have enrolled the first mesothelioma patients in a study that will combine their drug with chemotherapy against this virulent cancer. The drug, currently known as CRS-207, is manufactured by Aduro Bio Tech, Inc. According to a company press release, CRS-207 is based on an attenuated (made less potent) version of Listeria monocytogenes, bacteria found in soil and water than can cause the food borne illness, Listeriosis. To make CRS-207, scientists at Aduro genetically modified the Listeria monocytogenes in order to produce a powerful immune response against cells that produce mesothelin. Mesothelin is a tumor-associated antigen produced by several types of cancer cells, including mesothelioma cells. Because it works in conjunction with the body’s…

  • | |

    Monoclonal Antibody a ‘Novel Treatment’ for Mesothelioma?

    ByAlex Strauss

    A drug currently used to treat colorectal cancer and some types of head and neck cancer may also offer a new way to combat mesothelioma. Malignant pleural mesothelioma is an asbestos-linked cancer that spreads across the mesothelial tissue surrounding the lungs. The disease is highly resistant to most conventional therapies and is often fatal within a year of diagnosis.  As the number of mesothelioma cases continues to increase in many developing counties, scientists around the world are studying mesothelioma cells for clues that could help them develop more effective treatments. One clue is the overexpression of epidermal growth factor receptor (EGFR). EGFR is overexpressed by mesothelioma cells and several other types of cancer cells. The monoclonal antibody cetuximab, which is derived…